Real-life experience of tildrakizumab 200 mg in complex psoriatic patients: a case series

• by Giulia Odorici, Cinzia Buligan, Carolina Fantini, Lucia Mantovani, Giulia Rech, Lidia Sacchelli

• July 14, 2026

The role of protein lactylation in skin diseases: from molecular mechanisms to potential therapeutics

• by Yue Zhang, Zhinan Shi, Xiaohui Mo, Qiang Ju, Zhanyan Pan

• July 1, 2026

Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b

• by Mark Lebwohl, Andrew Blauvelt, Cynthia E. Kartman, Cianna Leatherwood, Kenneth B. Gordon, Naveed Sattar, Luis Puig, Joseph F. Merola, Kimberly Siu, Rona Wang, Luna Sun, Ann Leung, Najwa Somani, Maria Jose Rueda, Anabela Cardoso, Mark C. Genovese, April W. Armstrong, Bruce Strober

• July 1, 2026

Psoriasis–AD Switching May Mimic Treatment Failure

Recognizing sustained switches between the two diseases can prevent premature discontinuation of effective biologics and point toward Janus kinase inhibitors, a 148-patient cohort suggests.

• by Andrea Surnit

• June 15, 2026

• 4 min